I-Mab Soars 11.11% on Lucid Capital Buy Rating

On May 30, 2025, I-Mab's stock price surged by 11.11% in pre-market trading, marking a significant rise that has captured the attention of investors and analysts alike.

Lucid Capital recently initiated coverage on I-Mab Biopharma, assigning a Buy rating and setting a target price of $5. This move has been a key driver behind the stock's recent momentum, which has seen gains of over 10% in the past week and 22% year-to-date. The firm's analyst emphasized I-Mab's focus on precision medicine and its robust pipeline, particularly highlighting the upcoming presentation of its ABL111 cancer treatment at the ESMO conference in July.

I-Mab's stock surge has also been fueled by its upcoming presentation at the Jefferies Global Healthcare Conference. This event is expected to provide further insights into the company's strategic direction and pipeline developments, potentially attracting more investor interest.